Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JR-441 in Mucopolysaccharidosis Type IIIA
NCT06095388Phase 2Active, not recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Oct 2029
- Modality
- Antibody Conjugates, Replacement Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of posnafusp alfa in mucopolysaccharidosis type III A, sponsored by JCR Pharmaceuticals. Started Oct 2023; status: active, not recruiting.
02
Drugs
posnafusp alfa
03
Conditions
mucopolysaccharidosis type III A
Beyond the preview
Go deeper on NCT06095388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095388.